
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
ZNF280B (zinc finger protein 280B) encodes a transcription factor that upregulates expression of MDM2, a regulator of p53 activity. ZNF280B has been reported to be highly expressed in prostate cancer cells, where increased expression is associated with reduced p53 levels and increased cancer cell growth. These findings indicate a role for ZNF280B in transcriptional regulation of pathways involving MDM2 and p53.
A human hepatocellular carcinoma model, MHCC97-H was established from a highly metastatic human hepatocellular carcinoma and selected for its invasive and metastatic phenotype. The cells originated from a liver tumor of a 39-year-old male and are classified as a human liver cancer cell line. MHCC97-H is characterized by a hypotriploid karyotype and has been used in studies of hepatocellular carcinoma invasion and metastasis.
Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?